Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
IF

NASDAQ · IFRX

InflaRx N.V.

Healthcare · Biotechnology

$1.68

Down-$0.10 (-5.95%)

Updated Oct 7, 2026, 1:51 AM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
69.1M
P/E ratio
-1.3
Dividend yield
0.00%
52-week range
$0.80 – $2.95
Volume
701.01K
Avg. volume
2.87M

Price performance · IFRX

IFRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

IFRX closed at $1.68 after 20 trading sessions, down 22.58% for the selected period.

Last close
$1.68
Period change
-22.58%
Period low
$1.68
Period high
$2.17
Daily close
View OHLC price history
IFRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.70$1.72$1.65$1.68701.01K
Oct 2, 2026$1.74$1.80$1.72$1.72422.16K
Oct 1, 2026$1.83$1.856$1.71$1.71369.96K
Sep 30, 2026$1.87$1.89$1.80$1.80302.5K
Sep 29, 2026$1.83$1.89$1.80$1.85268.4K
Sep 28, 2026$1.88$1.9544$1.80$1.82426.39K
Sep 25, 2026$1.94$2.04$1.87$1.89399.9K
Sep 24, 2026$1.97$2.02$1.89$1.93510.19K
Sep 23, 2026$2.08$2.09$1.96$1.96564.76K
Sep 22, 2026$2.12$2.19$2.041$2.08571.27K
Sep 21, 2026$2.11$2.19$2.065$2.12345.15K
Sep 18, 2026$2.07$2.11$2.0254$2.09292.68K
Sep 17, 2026$2.05$2.10$1.98$2.06657.95K
Sep 16, 2026$2.02$2.0689$1.99$2.04821.21K
Sep 15, 2026$2.12$2.165$1.99$2.02579.6K
Sep 14, 2026$2.15$2.20$2.10$2.12545.79K
Sep 11, 2026$2.07$2.11$2.04$2.09334.15K
Sep 10, 2026$2.05$2.07$1.98$2.05613.48K
Sep 9, 2026$2.15$2.15$2.05$2.09759.75K
Sep 8, 2026$2.19$2.26$2.11$2.17408.9K

Latest IFRX news

The latest Smart Investors Daily articles mentioning IFRX.

Stock researchCompany · Overview

IFRX research

Overview

Company profile and research snapshot.

Company profile

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
IFRX recent ratings
DateFirmRatingTarget
Sep 14, 2026NeedhamBuy—
Aug 7, 2026Cantor FitzgeraldOverweight—
May 13, 2026Raymond JamesStrong Buy—
May 11, 2026HC Wainwright & Co.Buy—
May 11, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026. Dr. Alperovich is a physician-scientist and nephrologist with more than two decades of experience in the global pharmaceutical industry, spanning senior leaders

Yahoo · Sep 21, 2026

InflaRx to Host Virtual Capital Markets Day

Event to be hosted on November 3, 2026 at 8:00 AM ESTFeatured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. The timing of the ev

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By